Medgenics granted U.S. patent for use of Epodure technology for EPO delivery

Medgenics announced a patent granted by the U.S. Patent and Trademark Office protecting the use of Medgenics’ Epodure Biopump technology for delivery of erythropoietin, or EPO. Medgenics is developing Epodure to address the need for safer, sustained treatment of anemia. The USPTO also allowed claims covering a similar method for delivery of clotting Factor VIII, underlying Medgenics’ Hemodure Biopump technology for sustained prophylactic treatment of hemophilia.